Back to results
US 2003/0199582 A1Published application
Tolterodine salts
AssigneePharmacia & Upjohn Company
InventorsMichael Hawley, Satish Kumar Singh, Walter Morozowich, Mark P. Warchol
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneePharmacia & Upjohn Company
InventorsMichael Hawley, Satish Kumar Singh, Walter Morozowich, Mark P. Warchol
Estimating the term…
The present invention concerns novel pharmaceutically active compounds, pharmaceutical compositions containing the same, the compounds for use as medicaments, and use of the compounds for the manufacture of specific medicaments. The present invention also concerns a method of treatment involving administration of the compounds. Specifically, the compounds are pharmaceutically acceptable salts of tolterodine or hydroxytolterodine, wherein the salt is of an acid selected from the group consisting of aliphatic mono- and dicarboxylic acids comprising from 7 to 24 carbon atoms, alkanedisulfonic acids comprising from 2 to 4 carbon atoms, naphthoic acid derivatives comprising from 11 to 27 carbon atoms, maleic acid and fumaric acid.
A pharmaceutically acceptable salt of tolterodine or hydroxytolterodine, wherein the salt is of an acid selected from the group consisting of aliphatic mono- and dicarboxylic acids comprising from 7 to 24 carbon atoms, alkanedisulfonic acids comprising from 2 to 4 carbon atoms, and naphthoic acid derivatives comprising from 11 to 27 carbon atoms.
Use of a pharmaceutically acceptable salt of tolterodine or hydroxytolterodine, wherein the salt is of an acid selected from the group consisting of aliphatic mono- and dicarboxylic acids comprising from 7 to 24 carbon atoms, alkanedisulfonic acids comprising from 2 to 4 carbon atoms, naphthoic acid derivatives comprising from 11 to 27 carbon atoms, maleic acid and fumaric acid, for the manufacture of a medicament for treating a disorder selected from the group consisting of asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, and urinary disorder.
A method of treating a disorder selected from the group consisting of asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, and urinary disorder, in a mammal, including man, comprising administering to said mammal, in need of such a treatment, a therapeutically effective amount of a pharmaceutically acceptable salt of tolterodine or hydroxytolterodine, wherein the salt is of an acid selected from the group consisting of aliphatic mono- and dicarboxylic acids comprising from 7 to 24 carbon atoms, alkanedisulfonic acids comprising from 2 to 4 carbon atoms, naphthoic acid derivatives comprising from 11 to 27 carbon atoms, maleic acid and fumaric acid.
Dependencies are inferred from the claim text.